With the comprehensive promotion of pharmaceutical market reform policies such as "4+7" volume procurement and two-invoice system, many domestic pharmaceutical companies are accelerating the extension of the industrial chain by enriching product lines, expanding production capacity, and acquiring to cope with challenges
such as intensified market competition.
For example, Dajia Vikang recently issued an announcement that the company and Kangera Co.
, Ltd.
, Kanger Biologics and Dongfang Lijun jointly invested in the establishment of a joint venture company - Dajia Vikang Biopharmaceutical Co.
, Ltd.
Pharmaceutical machinery companies are accelerating the extension of the industrial chain layout (Image source: Pharma.
com)
It is understood that the purpose of this acquisition is to extend the company's industrial chain layout
.
Taking this transaction as an opportunity, Dajia Vikang will accelerate its layout to the upstream pharmaceutical industry and give full play to the company's existing business advantages and the synergistic effect
of the target asset business.
On August 9, Duorui Pharmaceutical issued an announcement that the company intends to acquire 40% of the shares of
Bozhou Tianji held by Hubei Tianji.
For the purpose of the acquisition, Duorui Pharmaceutical said that it is conducive to accelerating the improvement of the company's traditional Chinese medicine industry layout and further enhancing the company's profitability
.
In addition, Sinopharm Group has been accelerating the layout of the entire industry chain
of traditional Chinese medicine through reorganization and integration in recent years.
According to the data, from 2013 to 2021, it has acquired a large number of enterprises
such as Yingtian Pharmaceutical, Tongjitang, Tianjiang Pharmaceutical, and Fangfang Pharmaceutical.
In the ten years from 2012 to 2021, Sinopharm's modern Chinese medicine sector has achieved significant improvement
in operating efficiency.
By the end of 2021, it will achieve an asset scale of 54.
605 billion yuan, an operating income of 32.
755 billion yuan, and a net profit of 2.
069 billion yuan
.
Industry analysts believe that under the influence of factors such as the continuous advancement of medical reform, the general trend of innovation, and the intensification of market competition, pharmaceutical companies are actively adjusting their development direction and extending the layout
of the pharmaceutical industry chain.
It is understood that in addition to the above-mentioned enterprises, since the beginning of this year, many pharmaceutical companies have also issued announcements such as acquisitions and cooperation, all of which are aimed at promoting the extended layout of the industrial chain and improving the productivity and market competitiveness
of enterprises.
It is worth mentioning that pharmaceutical equipment is the upstream of the pharmaceutical industry, and from the current point of view, many enterprises in this field are also accelerating the extension of the industrial chain
under the background of fierce market competition and product homogenization.
On October 17, Dongfulong issued an announcement that the China Securities Regulatory Commission approved the company's registration application
for issuing shares to specific targets.
The company intends to raise no more than 3.
2 billion yuan, mainly to increase the production capacity of pharmaceutical equipment and replenish working capital
.
According to the announcement, after deducting the issuance expenses, 530 million yuan will be used for the biopharmaceutical equipment industry trial production center project, accounting for 16.
6%; 990 million yuan was used for the Jiangsu biomedical equipment industrialization base project, accounting for 30.
9%; 1.
25 billion yuan was used for the Hangzhou Life Science Industrialization Base Project, accounting for 39.
1%; A further $430 million will be used to replenish working capital
.
On October 19, Chutian Technology and Ningxiang Economic Development Zone signed a cooperation framework agreement on the Chutian biomedicine and life science industry chain, and the two sides will work together to build an enterprise-oriented industrial chain established in Ningxiang with strong support from the province and city, and further promote the construction and development
of the industrial chain.
Prior to this, on August 2, Chutian Technology also announced that it planned to invest 25.
5 million yuan to jointly establish a company with the main business of providing equipment, consumables and accessories related to cell processing systems in Changsha Ningxiang City
, Hunan Province.
At present, pharmaceutical companies have become a general trend to accelerate the extension of the industrial chain, and affected by this, many industries in the pharmaceutical industry chain will also usher in opportunities, such as the pharmaceutical equipment industry
.
The industry expects that in the future, pharmaceutical machinery companies will step up their efforts to extend the layout of the pharmaceutical industry chain through innovation and expansion, and further enhance their competitiveness
while continuously meeting the needs of the pharmaceutical industry.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
